Market Overview

Jefferies' Best Biotech Ideas For 2016 (And Beyond)

Share:
Jefferies' Best Biotech Ideas For 2016 And Beyond

In a report issued Wednesday, Jefferies’ Biotechnology Equity Research Team shared its outlook, key themes and best ideas in the biotechnology industry for 2016 and beyond.

After a volatile 2015, the experts assured they would be selective into the new year as sector headwinds (like "election-year drug pricing rhetoric" and maturing and increasingly crowded markets) persist. Having said this, they noted that "solid underlying fundamentals and potential for stabilization" lead them to believe substantial long-term value could still be unlocked in some companies.

Going forward, they see nice returns coming from biotechs with products that treat unique populations, which are highly differentiated, and in new or large markets not served optimally yet.

Top Picks

The note went on to look into Jefferies’ top picks in the biotech segment.

Among large-caps the experts like Biogen Inc (NASDAQ: BIIB) for its "likely MS franchise resiliency and under-appreciated pipeline readouts." They also think Celgene Corporation (NASDAQ: CELG)'s multiples could expand, reacting to "commercial execution and dataflow with IP overhang now removed."

In the mid-cap space, the analysts favor The Medicines Company (NASDAQ: MDCO), due to expectations for favorable ALN-PCSsc and carbavance data in the second half of the year; Swedish Orphan Biovitrum publ AB (STO:SOBI), on the back of the potential for 39 percent EPS CAGR driven by hemophilia launches; and Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), for its low-risk rich catalysts for the second half of 2016.

Top small-caps picks include Alder Biopharmaceuticals Inc (NASDAQ: ALDR), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Ignyta Inc (NASDAQ: RXDX), Oncomed Pharmaceuticals Inc (NASDAQ: OMED) and TherapeuticsMD Inc (NYSE: TXMD).

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Latest Ratings for BIIB

DateFirmActionFromTo
Nov 2020RBC CapitalMaintainsSector Perform
Nov 2020DZ BankUpgradesHoldBuy
Nov 2020B of A SecuritiesDowngradesNeutralUnderperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

 

Related Articles (BIIB + CELG)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Small Cap Analysis Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com